Phase III trial in 766 women with stage II-III HER2-positive breast cancer: neoadjuvant taxane, trastuzumab and pertuzumab without carboplatin was non-inferior to with carboplatin for pCR (64.1% vs 65.9%), with fewer grade 3-4 AEs (20.7% vs 34.6%).
RCTn = 774
Gao et al. Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial